In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.
Cannabidiol as potential treatment in refractory pediatric epilepsy / Paolino, MARIA CHIARA; Ferretti, Alessandro; Papetti, Laura; Villa, MARIA PIA; Parisi, Pasquale. - In: EXPERT REVIEW OF NEUROTHERAPEUTICS. - ISSN 1473-7175. - STAMPA. - 16:1(2016), pp. 17-21. [10.1586/14737175.2016.1121098]
Cannabidiol as potential treatment in refractory pediatric epilepsy
PAOLINO, MARIA CHIARA;FERRETTI, ALESSANDRO;PAPETTI, LAURA;VILLA, MARIA PIA;PARISI, Pasquale
Ultimo
Writing – Original Draft Preparation
2016
Abstract
In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.File | Dimensione | Formato | |
---|---|---|---|
Paolino_Cannabidiol_2016.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
2.66 MB
Formato
Adobe PDF
|
2.66 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.